Skip to Main Content

Paper Details

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.
Cancer Discov
61
2021
/, ADC, E418K, RNA, Sacituzumab Govitecan, T256R, TACSTD2, TOP1, TOP1 E418K resistance mutation, TOP1 mutation, TROP2, TROP2T256R, Triple-Negative Breast Cancer, anti-TROP2 antibody, hRS7, metastatic subclones, patient, payload, topoisomerase-1, triple-negative breast cancer
Author NameAffiliation
Ignaty LeshchinerBroad Institute of MIT and Harvard
Kahn Rhrissorrakrai
Steven J IsakoffMassachusetts General Hospital Cancer Center
Steven J IsakoffHarvard Medical School
Gad GetzMassachusetts General Hospital Cancer Center
Gad GetzMassachusetts General Hospital
Gad GetzBroad Institute of MIT and Harvard
Gad GetzHarvard Medical School
Gad GetzMassachusetts General Hospital Cancer Center
Gad GetzHarvard Medical School
Gad GetzBroad Institute of MIT and Harvard
Gad GetzMassachusetts General Hospital
Aditya BardiaMassachusetts General Hospital Cancer Center
Aditya BardiaHarvard Medical School
  • 1 - 14

Datasets

Release 1.2